ARCA biopharma, Inc. (NASDAQ: ABIO) exhibited a parabolic ascent on the trading session following the announcement of an all-stock merger with Oruka Therapeutics, a transaction poised to diversify the company's dermatological biologics portfolio. The equity's volume thrust was monumental, significantly eclipsing its 50-day average, indicating an accumulation of...
On the daily chart the trend started on January 27 (linear regression channel). And it is still not closed according to my calculations.
There is a high probability of profit taking. Possible take profit level is 2.81
But we should not forget about SL = 1.84
Using a trailing stop is also a good idea!
Please leave your feedback, your opinion. I am very...
Another extreme oversold small bio cap. Arca Biopharma Inc (NASDAQ:ABIO) touched a new 52 week low last week and closed at $2.36 a share on Friday. I think now is the time to start trying to catch this knife. Alone this company has more cash ($4 per share) than current market capitalization. Cash and cash equivalents were $58.3 million as of September 30, 2021,...
On this episode of "Between Two Fibs" ABIO once again tested the 618 line plotted after using the recent low as the anchor. This has been a failure point 2 other times in the last few weeks but with a little more afternoon momentum, it will be interesting to see if it can break and hold above it. Other than that, the 786 fib appeared to have acted as lower...
VERY RISKY, VERY LONG TERM INVESTMENT in Penny Stocks!!! Not a financial advice!
Buy - 3.50
TP - Sell limit at 21$ (2/3 of shares purchased)
1/3 - if go more up.
Good Luck!
ARCA biopharma Inc is a biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The firm's lead product candidate is Gencaro. The company adopts genotype-directed comparative effectiveness trial of Bucindolol and Toprol-XL for prevention of symptomatic atrial fibrillation in patients...
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the...
Abio whilst currently tumbling down pyramid slope has no dilution risk with sufficient cash on hand to last a while based on current cash burn and has plenty catalysts. Geometric structure is very supportive of a move to $12 at minimum and more likely $24
I'm really into crypto and I've seen so many things not only from a trading perspective but also mining individual Scrypt + SHA-256 coins...Fidelity is just an island or oasis with the peace of mind when I execute a trade it goes through. I don't have lag, loss of connection, obfuscation or loss of funds from theft on exchanges part. I can put $500 or 2 million...
